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A fluorescence nanoscopy marker for Corticotropin-Releasing 
Hormone type 1 receptor: computer design, synthesis, signaling 
effects, super-resolved fluorescence imaging, and in-situ affinity 
constant in cells.
Alan M. Szalaia,b,†, Natalia G. Armandoc,d,†, Federico M. Barabasa,e,†, Fernando D. Stefania,e, Luciana 
Giordanoa,f, Sara E. Barig, Claudio N. Cavasottoc,†, Susana Silbersteinc,h,†, Pedro F. Aramendíaa,b, †
Class B G protein-coupled receptors (GPCRs) are involved in a variety of human pathophysiological states. These groups of 
membrane receptors are less studied than class A GPCRs due to the lack of structural information, delayed small molecule 
drug discovery, and scarce fluorescence detection tools available. The class B Corticotropin-Releasing Hormone type 1 
Receptor (CRHR1) is a key player in the stress response whose dysregulation is critically involved in stress-related 
disorders: psychiatric conditions (i.e. depression, anxiety, addictions), neuroendocrinological alterations, 
neurodegenerative diseases. Here, we present a strategy to label GPCRs with a small fluorescent antagonist that permits 
the observation of the receptor in live cells through stochastic optical reconstruction microscopy (STORM) with 23 nm 
resolution. The marker, an aza-BODIPY derivative, was designed based on computational docking studies, then 
synthesized, and finally tested in biological cells. Experiments in hippocampal neurons demonstrate antagonist effects in 
similar concentrations as the well-established antagonist CP-376395. A quantitative analysis of two color STORM images 
enabled the determination of binding affinity of the new marker in the cellular environment.
Introduction
Corticotropin-releasing hormone type 1 Receptor (CRHR1) 
belongs to the class B family of G-protein-coupled 
receptors GPCRs.1 GPCRs are the largest group of 
membrane proteins, targets for about one third of 
pharmaceutical agents.2 Structural studies of 
transmembrane domains (TMDs), that couple GPCR 
activation to signaling effectors, were delayed for class B 
members in relation to class A GPCRs. CRHR1 and the 
glucagon receptor were the first two class B TMD crystal 
structures solved.3, 4
The corticotropin-releasing hormone (CRH) is a 41-aa 
peptide ligand for CRHR1, crucial in the integration of 
neuroendocrine, autonomic, and behavioral responses to 
stress.5 CRH-activated CRHR1 triggers a variety of cellular 
responses, leading to cAMP increase and activation of 
multiple signaling cascades.6 Dysregulation of the 
CRH/CRHR1 responses in the central nervous system is 
related to mood disorders as anxiety and depression,7 
psychiatric conditions that affect about 15% of the 
population.8 Knowledge of the subcellular spatial 
distribution and pathways of CRHR1 in a neuronal cell 
context appears as key for the understanding of its 
pathophysiological action.9
Fluorescence nanoscopy is becoming the preferred 
visualization tool to decipher subcellular protein structures, 
interactions and pathways.10-12 These techniques rely on 
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switching the fluorescent probes between an emissive and 
one or more non-emissive states. This gives special 
relevance to the photophysical properties of the 
fluorophores,13 whose brightness, contrast, photostability 
and switching performance determine the achievable 
spatial resolution.14 A remarkable recent advance has 
brought this limit to 1 nm,15 practically the size of the 
fluorophore. Ultimately, the achievable resolution of 
nanoscopy methods is limited by the physical size of the 
fluorescent label.
Various fluorescent labeling strategies are available to 
study biomolecules:16,17 the production of fusion 
proteins,18 labeling by post translational modification,19,20 
or the design of a fluorescent ligand for a specific protein.21 
Targeting a particular protein with a small molecule is the 
most challenging approach because it requires specific 
design and synthesis, but has a number of advantages: i) it 
avoids transfection, which allows its direct use in living cells 
and studies under endogenous cellular protein expression 
conditions; ii) It enables the application of fluorescence 
nanoscopy in its full potential.; and iii) it provides more 
reliable information about protein-protein interactions. 
While different fluorescence labeling approaches have 
been proposed and carried out for GPCRs,22-25 tagging the 
antagonist site with small probes appears as an interesting 
alternative.22,23,26 In the past few years, small molecule 
targeting of GPCRs with photoswitchable ligands to 
remotely control receptor activation have been 
reported.27-30 Specifically for CRHR1, there is a variety of 
high affinity synthetic non-fluorescent antagonists that 
modulate CRH effects.8,31-33 One of them, CP-376395, was 
crystallized with CRHR1.3
All these facts encouraged us to design a fluorescent probe 
for super-resolution fluorescence microscopy that would 
bind to the antagonist site of CRHR1. Figure 1 summarizes 
the strategy of this work. First, the structural analysis of 
effective synthetic antagonists was used to propose 
fluorescent structures that were analyzed by docking 
studies. The chosen candidate proved very effective as 
CRHR1 antagonist and showed excellent features for 
fluorescence nanoscopy. The fluorophore was used 
together with fluorescent immunolabeling of CRHR1 to 
estimate the binding equilibrium constant in neuronal cells 
by two color stochastic optical reconstruction microscopy 
(STORM).
Results and Discussion
Figure 1: The structure of CP-376395 and ONO-2333MS, synthetic antagonists of 
CRHR1, inspired the proposal of fluorophore ABP-09 as a ligand for the antagonist 
site of CRHR1.
Design and synthesis of ABP-09
We selected an aza-BODIPY scaffold as the basis for the 
fluorescent marker for the well described fluorescent 
features of this type of compounds, for the versatility of 
the spectral and photochemical properties, which can be 
modulated by substitution, and for their photochemical 
stability.34,35 We performed in silico docking onto CRHR1 
(PDB: 4K5Y) of structures ABP-01 to ABP-11 (see Table S1), 
compared to the co-crystallized ligand CP-376395 and to 
ligand ONO-2333Ms31 as controls. It was implemented with 
a flexible-ligand--rigid-receptor approach in the ICM 
software.36,37 Evident docking difficulty prevents pluri-
aromatic substitution in ABPs. This is a strong constraint for 
aza-BODIPY synthetic feasibility (see below).
Computational chemistry results, combined with 
photochemical stability criteria, showed that ABP-09 was 
the best candidate among the proposed structures to act 
as a stable antagonist for CRHR1, as we explain in what 
follows. The lowest-energy pose of CP-376395 exhibited a 
RMSD of 0.4 Å compared to the crystal structure, while 
ONO-2333Ms pose showed a consistent overlap with it 
(Figure S9). These two ligands, as well as all ABP proposed 
structures through its central nitrogen, establish a key H-
bond with N2835.50 (Wootten numbering shown in 
superscript38). Due to the approximations involved, docking 
scores may correlate poorly with binding affinities,39,40 so a 
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simple energy rescoring was performed, using a flexible-
ligand—flexible-receptor methodology, similar to the 
ligand-steered approach,41-43 but replacing the stochastic 
sampling by a faster local energy minimization. We omitted 
the entropic component of the free energy, since only a 
semi-quantitative estimation of the binding free energy is 
sought. According to this approach, the binding free energy 
trend is:
CP-376395<ONO-2333Ms~ABP-09~ABP-11~ABP-10.
Considering the chemical stability provided by the methyl 
substituents in positions 3 and 5 (Table S1), we chose ABP-
09 as the antagonist candidate, among the three best ABP 
structures. Figure 2 compares the docking of CP-376395 
and ABP-09. In ABP-09, the 2,4-dichlorophenyl group 
occupies the same region as the 2,4,6-trimethylphenyl 
group of CP-376395.
Figure 2. A) Docking of CP-376395 (grey carbons) and ABP-09 (light yellow 
carbons). B) Docking of ABP-09. Dotted lines display the H-bond to N2835.50. 
CRHR1 helices are displayed as light grey ribbons, and key interacting amino-acids 
as sticks. Color code: grey, carbon; blue, nitrogen; red, oxygen; green: chlorine. 
(Figure prepared with ICM, Molsoft LLC).
The synthetic route for ABP-09 is depicted in Figure 3. The 
pathway was designed taking advantage of the intrinsically 
asymmetric reaction mechanism,44,45 and avoiding the 
isolation of an unstable nitroso pyrrole intermediate. 
As almost all aza-BODIPYs described are tetra aryl 
substituted,44,46 the synthesis of the ABP-09 posed a 
challenge. The overall yield of ABP-09 is less than 1% 
starting from compound 2, but upon isolation this new 
compound was thermally and photochemically stable.
Figure 3 Synthetic route for ABP-09.
Spectroscopic properties of ABP-09
The absorption coefficient 530= (70 ± 10) 103 M-1 cm-1, was 
derived by comparison to BODIPYs and aza-BODIPYs of 
similar structure and energy.47-50 
ABP-09 displays a moderate negative solvatochromism. 
The energy of the maximum absorption and emission 
wavelength as well as the Stokes shift show a linear 
dependence with the ET(30) solvent parameter, as 
displayed in Figure S10. Absorption and emission maxima 
are located at 535 and 552 nm in toluene, at 529 and 550 
nm in dichloromethane (see Figure 4A), at 517 and 544 in 
acetonitrile, and at 518 and 546 nm in methanol, 
respectively (Figure S10). Most BODIPY compounds show a 
very mild positive solvatochromism that is greatly 
enhanced when electron donating and withdrawing 
substituents.51 Interestingly, a recent work reports the 
negative solvatochromism of a group of push-pull aza-
BODIPYs with the same substitution pattern in both indole 
rings.52 The magnitude of the solvatochromic shift in 
absorption between toluene and acetonitrile is similar to 
ABP-09, a compound that has moderate electron attracting 
and donating groups in only one ring.
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The red shift (>35nm) in the maximum absorption 
wavelength of ABP-09 as compared to the 1,3,5,7-methyl 
substituted BODIPY53 is a consequence of the aza-BODIPY 
structure. Indeed, such a red-shifted absorbance cannot be 
explained in terms of an extended conjugation introduced 
by the 2,4-dichlorophenyl substituent in position 1. This 
statement is based on the electron withdrawing properties 
of the chlorine atoms present in the substituent and the 
low impact of substituents in position 1 to bathochromic 
shifts.51,53,54 Taken together, these considerations support 
that the observed red shift is a consequence of the effect 
of the N atom in the meso position.51,55
The emission in dichloromethane has a quantum yield of 
0.86 ± 0.04, and a lifetime of 3.84 ± 0.01 ns (exc = 490 nm, 
Figure 4B).
Figure 4. A) Absorption (green line) and fluorescence emission (blue line, exc = 
490 nm) and excitation (red line, em = 590 nm) spectra of ABP-09 in DCM. Spectra 
are normalized to their respective maximum. B) Emission decay in DCM. Black line: 
Instrument response function (IRF). Red line: experimental decay. Blue line: Fit to 
the data of a convolution of a monoexponential decay with 3.84 ± 0.01 ns and the 
IRF.
ABP-09 and CP-376395 effect on CRH-activated CRHR1 
signaling
The influence of ABP-09 and the CRHR1 antagonist CP-
376395 in signaling effectors downstream CRH-activated 
CRHR1 was tested in HT22-CRHR1 and in HT22-CRHR1-
Epac-SH187 cells, stably expressing CRHR1 and both CRHR1 
and the FRET-based biosensor for cAMP Epac-SH187, 
respectively (see Materials and Methods and SI).56 First, 
using HT22-CRHR1-Epac-SH187 cells, 10 nM CRH stimulation 
triggered a rapid and sustained cAMP response (Figure 5) 
as previously reported.56 In cells preincubated with either 
ABP-09 or the antagonist CP-376395 in 10 or 100 nM 
concentration, cAMP levels decreased similarly compared 
to control conditions (Figure 5). The preincubation used 
before stimulation was 20 h, time after which ABP-09 
concentration in living cells attains a level independent of 
the initial dose that remains constant in time (see 
Materials and Methods and Figure S12). For both species, 
the 50% decrease in the FRET response demonstrates an 
inhibiting effect in this CRHR1 signaling pathway with 
comparable effectiveness for ABP-09 and CP-376395, 
showing saturation effect at 10 nM concentration added.
Further evidence of ABP-09 antagonist action was obtained 
from the analysis of the activation (phosphorylation) of 
signaling proteins downstream stimulated CRHR1. Cells 
were also preincubated during 20 h with ABP-09 in these 
experiments. Two phosphoprotein levels were assessed by 
Western Blot in HT22-CRHR1 cells stimulated with 100 nM 
CRH: pERK1/2, monitored 5 minutes after stimulation and 
pAkt, monitored 30 minutes after stimulation57 Whereas 
no effects were observed in basal phosphoprotein levels, 
when either 100 nM or 1 M ABP-09 was present there 
was a decrease to 75% of the maximum response in 
pERK1/2 after 5 minutes of stimulation. A decrease in pAkt 
was evidenced 30 minutes after stimulation in cells treated 
with the mentioned concentrations of ABP-09 (about 90-
70% of the maximum pAkt response, Figure S13).
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Figure 5. cAMP response measured by FRET in single HT22-CRHR1-Epac-SH187 
cells, stimulated with 10 nM CRH at time 0 (mean ± SEM n= 14-25 cells) and 
preincubated with: A) ABP-09; B) CP-376395.
ABP-09 as a fluorescent probe for in vivo CRHR1 labeling and 
STORM imaging
The performance of ABP-09 was benchmarked against 
Alexa Fluor 647, one of the best-performing fluorophore 
for STORM. Two-color STORM imaging was performed in 
the HT22-CRHR1 cell line which expresses CRHR1 with a 
cMyc tag at the N-terminus (cMyc-CRHR1). Cells were 
treated with 10 nM ABP-09 during 20 h, fixed, and the 
cMyc tag was detected by indirect immunofluorescence 
using a specific anti-cMyc primary antibody and a 
secondary antibody labeled with Alexa Fluor 647 (Figure 6). 
The localization precision in single molecule localization 
depends on the width of the Point Spread Function (PSF) of 
the microscope, the pixel size of the detector, the number 
of photons collected per event, and the background 
noise.58 High photon counts per frame favour location 
precision, while a low fraction of time in the on state 
allows location of the molecule in the presence of others as 
well as increases location speed.59 Consequently, the 
brightness and blinking performance of ABP-09 was 
measured in comparison to Alexa Fluor 647. ABP-09 
molecules show an average ON time of 33 ms compared to 
35 ms for Alexa Fluor 647 (30 ms exposure time), while the 
ratio between photons emitted by Alexa Fluor 647 and 
ABP-09 molecules is 2.5 ± 0.5, both under incident laser 
excitation of (6 ± 1) kW.cm-2 (see Figure S11). The 
photostability of ABP-09 is also comparable to Alexa Fluor 
647. Images have a lateral localization precision of 26 ± 7 
nm for Alexa Fluor 647, and 23 ± 7 nm for ABP-09 (Figure 
6C). These results demonstrate the excellent features of 
ABP-09 as a probe for STORM. The slightly lower 
localization precision for Alexa Fluor 647 compared to ABP-
09 in spite of the higher brightness of the former probe is 
attributed to two factors. The first one is the higher 
background observed in the Alexa Fluor 647 emission 
channel (Figure S11). The second one is the size (~10 nm) 
of the multiple fluorophore labelling of the secondary 
antibody. Instead, ABP-09 provides a true single molecule 
label to each receptor. The lower brightness of ABP-09 
compared to Alexa Fluor 647 is explained by the lower 
absorption coefficient at the excitation wavelength: 7x104 
M-1cm-1 and 2.4 105 M-1cm-1, respectively. This brightness 
and stability places ABP-09 among the best performing 
dyes for single molecule localization in the green light 
excitation range.59
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Figure 6.  STORM images of labelled HT22-CRHR1 cells. Alexa Fluor 647 conjugated 
to antibodies (red channel) and ABP-09 (green channel). A) Whole cell image and 
B) Zoom in of the area marked in A. C) Histogram of the localization precision of 
single molecules for the two dyes. Scale bars: A) 2 m; B) 500 nm.
Analysis of the molecular association between CRHR1 and 
ABP-09
Several methods have been reported to extract 
quantitative information of molecular association from 
fluorescence nanoscopy images, such as cluster 
distribution, pair correlation function, or point patterns, to 
statistically estimate significance in approach beyond the 
statistical random crowding.60-66 Here we obtain an 
approximation to thermodynamic association equilibrium 
constants, by computing association coefficients Qij = 
Nij/(Ni.Nj), based on direct counting single and paired 
molecules (i,j representing either of the fluorophores). A 
comparison with simulated random distributions provides 
the reference and calibration of the method (see SI for 
detailed description). Figure 7A shows that the actual 
distributions, where HT22-CRHR1 cells were incubated for 
20 h with 10 nM ABP-09, computed in different areas of 
various cells, always present greater association than that 
expected for random pairing. This result is in line with ABP-
09 antagonistic effect on CRHR1 signaling. The effect of 
adding for 15 minutes the non-fluorescent CRHR1 
antagonist CP-376395 in a large excess (10 and 100 M) to 
HT22-CRHR1 cells incubated with 10 nM ABP-09, is also 
shown in Figure 7A. These last two curves match to a large 
extent and exhibit a lower fraction of ABP-09 / CRHR1 
association events when compared to cells untreated with 
CP-376395. This observation confirms a displacement of 
ABP-09 from CRHR1 by the dark antagonist. Additionally, 
the indistinguishable behavior observed for the 10 and 100 
M CP-376395 treatments suggests that a complete 
displacement is achieved with the lower concentration 
tested. Figure 7B includes the analysis of the neighborhood 
between ABP-09 and CRHR1 in HT22 cells (not expressing 
cMyc-CRHR1) and compares it with the displacement 
experiments described for Panel A. The association 
observed in HT22 cells reflects both random pairing and 
unspecific binding of labeled antibodies and ABP-09. In 
both situations (HT22 cells and displacement experiments) 
the fraction of associated molecules was very similar and 
significantly lower than the one calculated from the 
experiments where HT22-CRHR1 cells were incubated with 
ABP-09 alone. This fact points out that CP-376395 and ABP-
09 are competitors in the association to CRHR1, and that, 
after displacement, the residual association observed is 
due to random pairing and unspecific binding.
We should note that Qab includes pairs not only originated 
in molecular affinity but also others due to random 
neighborhood. Images show that ABP-09 and Alexa Fluor 
647 also appear as self-associated (Figure 6). Therefore, we 
considered also the corresponding association constants to 
describe the molecular distribution of the whole system 
(see Figure S14 for Qaa and Qbb). The relation between Qij 
and their corresponding Kij was explored by simulations of 
molecular distributions with different values of Kab, Kaa, and 
Kbb as a function of molecular density. In these simulations 
Qij was computed and normalized to the corresponding 
random distribution (Qij,rndm, all Kij = 0) with the same 
density, characterized by the parameter Rab = 
log(Qab/Qab,rndm). The results show that Rab is constant to 
within ± 0.3 logarithmic units as a function of molecular 
density in a broad range of molecular density (Figure S15), 
providing a good calibration criterion.
From experimental data of Figure 7 we obtain Rab = 0.31 ± 
0.11 (data of Figure 7 shown as logarithmic ratio in Figure 
S17). Assuming that Kaa = Kbb, due to the similar values of 
Qaa and Qbb (Figure S14), we obtain log Kab = - 4.1 ± 0.2, and 
log Kaa = log Kab = - 3.2 ± 0.2. The observation volume of 
1.35 109 nm3 was calculated considering the 200x200 pixels 
of 13x13 nm2 area used as standard and an estimated TIRF 
irradiation depth of 200 nm. With it, Kab = 8 104 M-1; Kaa = 
Kbb = 5 105 M-1 are obtained. We will focus here in Kab, as it 
represents the association between ABP-09 and CRHR1.
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The dissociation constant of the ABP-09-CRHR1 complex 
(the inverse of Kab) has a value of 12 M. This value is 
around three orders of magnitude greater than those for 
potent CRHR1 antagonists.31,32 Nevertheless, inhibition 
experiments demonstrate that ABP-09 and CP-376395 
exert similar inhibiting cellular effects at the same nM bulk 
concentration range. The association constant we inform is 
obtained in a cell environment, where local concentration 
is higher than the average value of the concentration 
provided. More precisely, the average molecular density of 
around 0.1 molecules per pixel (the volume corresponding 
to a pixel is 13x13x200 nm3) is equivalent to a 
concentration of 5 M. It represents a 500-fold 
concentration increase compared to the 10 nM ABP-09 
concentration added to the cell preparation to perform the 
experiments. Therefore, we can assess that the 
dissociation equilibrium constant of ABP-09-CRHR1 in bulk 
experiments would also lie in the nM range, as most potent 
known antagonists.
In reference to the value of the dissociation constant, some 
observations deserve consideration. In the first place, this 
estimation does not exclude from the analysis the possible 
unspecific binding of ABP-09 directly to labeled antibody. 
Experiments in HT22 cells could be an estimation of this 
fact, but this is not the only possible interpretation of these 
results (see below). Secondly, it considers each isolated 
ABP-09 or labeled antibody as free molecules, while they 
could also be associated to different cell components. 
Thus, these phenomena may result in an overestimation 
not only of molecular pairing, but also of the total number 
of free ABP-09 and/or CRHR1. Both effects tend to 
compensate.
Figure 7. A) Scheme of the association of ABP-09 to immunolabeled CRHR1 
and definition of the pairing coefficient Qab. “a” stands for Alexa Fluor 647 
and “b” stands for ABP-09. B) Plot of pairing coefficient Qab as a function of 
the average number of molecules per pixel in various regions of different 
HT22-CRHR1 cells treated with 10 nM ABP-09 (violet dots and curve; 3 cells, 
with 7, 7, and 6 areas examined) and for the same system after addition of 
10 and 100 µM CP-376395 (blue and green dots/curves, respectively; 2 cells 
for each concentration, with 5 areas analyzed in each cell treated with 10 
µM CP-376395, and 5 and 6 areas in the 100 µM CP-376395 condition). Black 
dots and curves represent the simulated distribution using the same 
molecular density as the experimental curves. C) Same as B) in HT22 cells 
treated with 10 nM ABP-09 (red dots and curve; 4 cells, with 2, 2, 4, and 6 
areas considered). Green and blue dots/curves are the same as in panel B, 
while black curve corresponds to the respective reference random 
simulation. Shadowed regions show the 95% confidence interval of the linear 
fits.
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A further concern regards the coincidence of the results in 
HT22 cells and in HT22-CRHR1 cells displaced with CP-
376395, as they systematically show a greater association 
than random simulations. If we assume that ABP-09 and 
CRHR1 are not associated to an appreciable extent in these 
experiments, the difference can be reasonably interpreted 
by assuming that the available space for CRHR1 and ABP-09 
location does not correspond to the whole cell volume, as 
used in the simulations. Under this interpretation the 
available volume reduction results in a density increase 
that would shift horizontally in Figure 7C the lines 
corresponding to the experiments in HT22 cells and in 
HT22-CRHR1 cells displaced with CP-376395 with respect 
to the random simulations. If we perform this shift to make 
the curves coincide in Figure 7C, a factor of two can be 
estimated in the density.
We consider the reported value of the dissociation 
constant of ABP-09-CRHR1 to be robust because: i) the 
addition of CP-376395 as displacement agent decreases 
the association, measured by the parameter Qab, to levels 
similar to the ones in cells that lack cMyc tag, and that can 
therefore be taken as reference for unspecific association 
ii) as assessed by the molecular density in the field of view, 
concentrations lie in the M range in the cell environment; 
iii) we observe variations in the fraction of associated and 
free molecules as a function of local concentration in 
different cell portions within this M range.
Conclusions
The molecular design strategy used here, that combined 
molecular docking and photochemical stability criteria, 
proved successful in producing a fluorescent marker for the 
antagonist site of CRHR1. ABP-09, an aza-BODIPY, shows 
excellent emission properties for stochastic single 
molecule-based fluorescence nanoscopy. Structural 
information for other members of Class B GPCRs is 
currently growing. Thus, the strategy described in this work 
for the design of fluorescent probes based on known 
crystallographic structures anticipates a great impact in 
labeling experiments. In a wider sense, small molecule 
markers for proteins are suitable for tracking experiments 
in live cells, tissues, and even in whole organisms because 
this rationale avoids in-vitro fusion protein production. In 
addition, we have developed an analysis method that is 
broadly applicable, to estimate association constants from 
high resolution localization microscopy images in cells.
Experimental Section
Computational chemistry. 
All simulations were based on the crystal structure of Class 
B GPCR CRHR1.3 The molecular system was described in 
the dihedral space using the ECEPP/3 force field67,68 within 
the ICM program36,37 and prepared in a similar fashion as in 
earlier works.69-71 Docking was performed within the 
orthosteric binding site after deleting all water molecules 
and co-factors, using a flexible-ligand—rigid-receptor 
approach as implemented in ICM. In the docking algorithm 
the torsional degrees of freedom (DOF) of the small-
molecules and their six rigid coordinates were considered 
flexible within the receptor energy field, and subjected to a 
Monte Carlo global energy minimization. On the lowest 
docking energy pose of each molecule an empirical docking 
score was calculated according to its fit within the binding 
site.72 To improve convergence of the global energy 
minimization step, docking was performed twice and the 
lowest score per molecule was kept. Docked structures 
were refined in a ligand-steered fashion, where the 
molecules’ DOF and receptor side chains within 6.0 Å were 
optimized using an energy minimization protocol (for a 
detailed description cf. Refs.41,43,73). 
Synthesis of ABP-09. 
The synthetic procedures and characterization of ABP-09 
and intermediate compounds 1, 2, and 3 (Figure 3) is 
described in the SI. The synthesis has been adapted from 
reported procedures. Characterization of final product and 
reaction intermediates was achieved by combination of 
analytical, spectroscopic, and spectrometric procedures 
(Figures S1-S7). Spectral characterization of ABP-09 was 
carried out by absorption spectroscopy, and steady state 
and time resolved fluorescence spectroscopy, as detailed in 
the SI. 
ABP-09 uptake in live cells. 
HT22-CRHR1 cells were incubated in phenol red free 
DMEM low glucose (Invitrogen) supplemented with 20 mM 
Hepes, 26 mM NaHCO3 and 10 nM or 100 nM of ABP-09. 
Fluorophore uptake kinetics in live cells was measured for 
24 h using widefield fluorescence microscopy. Cell imaging 
conditions and fluorescence quantification protocols are 
described in the SI. In Figure S12 the temporal evolution of 
emission arising from live cells is shown. From these 
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experiments, we selected a 20 h preincubation time for 
ABP-09 when used in cells.
Spectral FRET and imaging of cAMP. 
HT22-CRHR1-Epac-SH187 cells were preincubated as 
described for HT22-CRHR1 cells in ABP-09 uptake 
experiments. To study the effect of CP-376395 (3212, 
TOCRIS), preincubation was carried in either 10 or 100 nM 
concentration of this compound. For control cells DMSO 
(vehicle) was used in the 20 h preincubation event. FRET 
experiments were carried out as previously described.56 
The acquisition conditions, image processing protocols and 
the characteristics of the fluorescence microscope are 
reported in detail in the SI. Briefly, HT22-CRHR1-EPAC-SH187 
cells were seeded in glass-bottom dishes, grown, and 
incubated with ABP-09, CP-376395 or DMSO, as previously 
described. After preincubation, cells were stimulated with 
10 nM of human/rat CRH (H-2435, Bachem) at time 0. 
Movies were recorded acquiring images every 15 s, from t 
= -2 min until t = 15 min, at the spectral channels 
corresponding to the FRET pair (mTurquoise2 and Venus) 
and to ABP-09.
Super-resolution fluorescence microscopy (STORM). 
For STORM microscopy, HT22-CRHR1 and HT22 cells were 
preincubated for 20 h in phenol red free DMEM low 
glucose (Invitrogen) supplemented with 20 mM Hepes, 26 
mM NaHCO3 and 10 nM ABP-09. For the antagonist 
displacement analysis, after the preincubation with ABP-
09, cells were incubated 15 min with 10 M or 100 M CP-
376395. Fixation, immunolabeling protocol and coverslip 
cleaning are described in detail in the SI. The STORM 
microscope was custom-built around an Olympus IX-73 
inverted microscope operating in wide-field 
epifluorescence mode (Figure S8). Two color images were 
acquired with an oil immersion objective Olympus PlanApo 
60x NA 1.42. Total internal reflection illumination mode 
(TIRF) was enabled by moving a linear stage (Thorlabs) so 
that the focus of the lasers translated laterally within the 
back focal plane of the objective. Fluorescent emission 
from different species were separated with a dichroic 
mirror (Chroma ZT647rdc) and imaged onto adjacent areas 
of the EMCCD camera (Andor iXon3 897). The camera and 
lasers were controlled with custom software developed in 
the laboratory and described in an earlier publication.74 A 
more extensive description of the microscope components 
can be found in the SI and Figure S8. The calibration 
protocol to find the affine transformation matrix for 
optimally overlapping the two emission channels is also 
presented in the SI. STORM data acquisition was carried 
out under laser intensities of 5-10 kW cm-2 for excitation, 
thus inducing on-off switching of the fluorescent markers 
in the tens of ms time range, as required by the STORM 
technique. A Pre-Amp Gain of 5.1 and an EM Gain of 40 
were used in the CCD camera. Throughout the whole 
acquisition, the activation 405 nm laser power was 
increased in steps whenever the density of single-molecule 
events decreased below ~1 molecule per μm2. Typically, it 
took 20,000 frames of 30 ms of exposition time for each 
STORM acquisition. The previously found affine 
transformation was then applied to the raw images. 
Subsequent data analysis and the rendering of the final 
super-resolved image were performed with 
ThunderSTORM software75 and finally the two color images 
were assembled with ImageJ/Fiji.76
Estimation of the CRHR1-ABP-09 binding constant. 
STORM images were processed with a 13.3 nm pixel size to 
locate the molecules. For the assessment of association, a 
9 pixel pattern was considered: the pixel where the central 
molecule was located and the 8 surrounding ones. Single 
molecule locations in a reconstructed STORM image were 
analyzed with custom MATLAB routines to count molecular 
pairs and isolated molecules. In this way Qij values are 
computed. To translate them into Kij values, simulated 
distributions for the random case and for different sets of 
values of Kij as a function of molecular density were used to 
calculate the ratio Qab/Qab,rndm in each case (FigureS15 for 
the simulations and FigureS17 for HT22-CRHR1 cells). The 
density-averaged value of Rab = log(Qab/Qab,rndm) was 
plotted as a function of input values of the Kij (FigureS16) 
to render the final calibration from which association 
constants can be estimated.
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